This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Kyto Technology and Life Science Past Earnings Performance

Past criteria checks 2/6

Kyto Technology and Life Science has been growing earnings at an average annual rate of 28%, while the Capital Markets industry saw earnings growing at 12.1% annually. Revenues have been growing at an average rate of 13.8% per year.

Key information

27.95%

Earnings growth rate

23.88%

EPS growth rate

Capital Markets Industry Growth	10.26%
Revenue growth rate	13.78%
Return on equity	8.79%
Net Margin	-129,032.08%
Last Earnings Update	31 Dec 2021

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Kyto Technology and Life Science makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

OTCPK:KBPH Revenue, expenses and earnings (USD Millions)
Date	Revenue	Earnings	G+A Expenses	R&D Expenses
31 Dec 21	0	1	0	0
30 Sep 21	0	1	0	0
30 Jun 21	0	0	0	0
31 Mar 21	0	0	0	0
31 Dec 20	0	0	0	0
30 Sep 20	0	0	0	0
30 Jun 20	0	-1	0	0
31 Mar 20	0	-1	0	0
31 Dec 19	0	0	0	0
30 Sep 19	0	0	0	0
30 Jun 19	0	0	0	0
31 Mar 19	0	0	0	0
31 Dec 18	0	0	0	0
30 Sep 18	0	0	0	0
30 Jun 18	0	0	0	0
31 Mar 18	0	0	0	0
31 Dec 17	0	0	0	0
30 Sep 17	0	0	0	0
30 Jun 17	0	0	0	0
31 Mar 17	0	0	0	0
31 Dec 16	0	0	0	0
30 Sep 16	0	0	0	0
30 Jun 16	0	0	0	0
31 Mar 16	0	0	0	0

Quality Earnings: KBPH has a large one-off gain of $2.5M impacting its last 12 months of financial results to 31st December, 2021.

Growing Profit Margin: KBPH became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: KBPH has become profitable over the past 5 years, growing earnings by 28% per year.

Accelerating Growth: KBPH has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: KBPH has become profitable in the last year, making it difficult to compare its past year earnings growth to the Capital Markets industry (2.4%).

Return on Equity

High ROE: KBPH's Return on Equity (8.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/11/19 16:37
End of Day Share Price	2022/08/22 00:00
Earnings	2021/12/31
Annual Earnings	2021/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kyto Technology and Life Science, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.